



Life is Rare

October 17, 2025
JCR Pharmaceuticals Co., Ltd.

Shin Ashida of JCR Pharmaceuticals Named Kansai Regional Representative in EY Entrepreneur of The Year™ 2025 Japan

Hyogo, Japan – October 17, 2025 – [JCR Pharmaceuticals Co., Ltd.](https://www.jcrpharm.com/) (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Shin Ashida, Chairman, President and CEO of JCR, has been selected as the Kansai Regional Representative in the “Regional Vitalization Leader” category at the EY Entrepreneur of The Year™ 2025 Japan (EOY 2025 Japan).

The EY Entrepreneur of The Year™ is a global awards program honoring entrepreneurs who demonstrate innovation, leadership, and long-term impact. Operating in more than 145 cities across 80 countries, it is recognized as one of the most prestigious business awards worldwide.

The Regional Vitalization Leader category recognizes entrepreneurs who:

- Drive measurable impact and contributions in their local community.
- Create unique, regionally originated value that influences both Japan and the global market.
- Blend tradition and innovation to achieve world-class technology and sustainable business models.
- Generate employment and long-term value while growing alongside their community.

Further details are available on the official EOY 2025 Japan website:

https://www.ey.com/ja_jp/entrepreneur-of-the-year-japan/eoy-2025-japan

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR’s global website: <https://jcrpharm.com/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com